Association of low-energy femoral fractures with prolonged bisphosphonate use: A case - Control study

Osteoporosis International

Volumn 20, Issue 8, 2009, Pages 1457-1458

  Vasikaran, S D ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bisphosphonates; Femur; Insufficiency fracture; Metastatic bone disease; Myeloma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; GLUCOCORTICOID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE MINERAL; BONE TURNOVER; CASE CONTROL STUDY; CROSS LINKING; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LETTER; LONG TERM CARE; MULTIPLE MYELOMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; MULTIPLE MYELOMA;

EID: 67650447735     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0955-5     Document Type: Letter

References (14)

1. BA Lenart AS Neviaser S Lyman 2008 Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos Int 10.1007/s00198-008-0805-x
2. EB Kwek SK Goh JS Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39 224 231
3. M Visekruna D Wilson FE McKiernan 2008 Severely suppressed bone turnover and atypical skeletal fragility J Clin Endocrinol Metab 93 2948 2952
4. BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate N Engl J Med 358 1304 1306
5. R Bataille 1996 Management of myeloma with bisphosphonates N Engl J Med 334 529 530 (Pubitemid 26067744)
6. N Raje SB Woo K Hande 2008 Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw Clin Cancer Res 14 8 2387 2395 (Pubitemid 351551072)
7. RA Kyle GC Yee MR Somerfield 2007 American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 2464 2472 (Pubitemid 46999218)
8. J Grasko RP Herrman SD Vasikaran 2009 Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates J Oral Maxillofac Surg 67 3 645 649
9. G Wernecke S Namduri EF Dicarlo R Schneider J Lane 2008 Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid HSSJ 4 2 123 127
10. LA Bush FS Chew 2008 Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastases Radiology Case Reports [online] 3 232 http://radiology.casereports.net/index.php/rcr/article/view/232/ 548
11. KH Yang JH Won HK Yoon 2007 High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model Yonsei Med J 48 653 658 (Pubitemid 47496728)
12. Zoledronic acid treatment (every 4 or 12 weeks) to prevent skeletal complications in advanced multiple myeloma patients (Z-MARK). http://www.clinicaltrials.gov/ct2/show/NCT00622505?term= zoledronic+acid+and+myeloma&rank=5
13. Study of zoledronic acid administered monthly versus every 3 months in multiple myeloma and breast cancer patients who were treated with zoledronic acid the prior year. http://www.clinicaltrials.gov/ct2/show/NCT00424983?term= zoledronic+acid+and+myeloma&rank=6
14. Bone marker assessment of multiple myeloma patients treated with aminobisphosphonates. http://www.clinicaltrials.gov/ct2/show/NCT00577642?term= bone+marker+assessment++myeloma&rank=1